Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

Shabir A Madhi; Anthonet L Koen; Alane Izu; Lee Fairlie; Clare L Cutland; Vicky Baillie; Sherman D Padayachee; Keertan Dheda; Shaun L Barnabas; Qasim Ebrahim Bhorat; Carmen Briner; Parvinder K Aley; Sutika Bhikha; Tandile Hermanus; Elizea Horne; Aylin Jose; Prudence Kgagudi; Teresa Lambe; Masebole Masenya; Mduduzi Masilela; Nonhlanhla Mkhize; Andrew Moultrie; Christian K Mukendi; Thandeka Moyo-Gwete; Amit J Nana; Ayanda Nzimande; Faeezah Patel; Sarah Rhead; Carol Taoushanis; Asha Thombrayil; Samuel van Eck; Merryn Voysey; Tonya L Villafana; Johan Vekemans; Sarah C Gilbert; Andrew J Pollard; Penny L Moore; Gaurav Kwatra

The Lancet HIV (2021) - Comments
pubmed: 34416193 doi: 10.1016/s2352-3018(21)00157-0 issn: 2352-3018

Shabir A Madhi, Anthonet L Koen, Alane Izu, Lee Fairlie, Clare L Cutland, Vicky Baillie, Sherman D Padayachee, Keertan Dheda, Shaun L Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Parvinder K Aley, Sutika Bhikha, Tandile Hermanus, Elizea Horne, Aylin Jose, Prudence Kgagudi, Teresa Lambe, Masebole Masenya, Mduduzi Masilela